Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023.
Jingrong YeYuan DongYun LanJing ChenYing ZhouJinjin LiuDan YuanXinli LuWeigui GuoMinna ZhengHong YangXiao SongCong LiuQuanhua ZhouChenli ZhengQi GuoXiaohui YangLincai ZhangZhangwen GeLifeng LiuFengting YuYang HanHuihuang HuangMingqiang HaoYuhua RuanJianjun WuJianjun LiQiang ChenZhen NingXuemei LingChang ZhouXuangu LiuJianyun BaiYa GaoXue TongKangping ZhouFanghua MeiZhengrong YangAo WangWei WeiRuijuan QiaoXinhua LuoXiao-Jie HuangJuan WangXin ShenFengyu HuLinglin ZhangWei TanJixiang FanAixia TuGuolong YuYong FangShufang HeXin ChenDonglin WuXinhui ZhangRuolei XinXin HeXianlong RenConghui XuYanming SunYang LiGuowu LiuXiyao LiJunyi DuanTao HuangYiming ShaoYi FengQichao PanBin SuTianjun JiangHongxin ZhaoTong ZhangFaqing ChenBing HuHui WangJin ZhaoKun CaiWei SunBaicheng GaoTielin NingShu LiangYuqi HuoGengfeng FuFeng LiYi LinHui XingHongyan LuPublished in: The Journal of infectious diseases (2024)
Presently, the continued use of NNRTI-based first-line antiretroviral therapy regimen for HIV treatment has been justified.